U.S. Markets close in 5 hrs 52 mins
  • S&P 500

    4,146.20
    -17.80 (-0.43%)
     
  • Dow 30

    34,094.69
    -62.00 (-0.18%)
     
  • Nasdaq

    12,040.86
    -72.93 (-0.60%)
     
  • Russell 2000

    1,961.66
    -10.95 (-0.56%)
     
  • Crude Oil

    77.91
    +0.77 (+1.00%)
     
  • Gold

    1,885.30
    +0.50 (+0.03%)
     
  • Silver

    22.34
    +0.17 (+0.76%)
     
  • EUR/USD

    1.0722
    -0.0009 (-0.0858%)
     
  • 10-Yr Bond

    3.6790
    +0.0050 (+0.14%)
     
  • Vix

    18.81
    +0.15 (+0.80%)
     
  • GBP/USD

    1.2057
    +0.0005 (+0.0422%)
     
  • USD/JPY

    131.4160
    +0.3440 (+0.2624%)
     
  • BTC-USD

    23,027.70
    +48.93 (+0.21%)
     
  • CMC Crypto 200

    531.80
    -5.10 (-0.95%)
     
  • FTSE 100

    7,908.35
    +43.64 (+0.55%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Mersana Inks Cancer Therapy Development Deal With Merck Germany

  • Mersana Therapeutics Inc (NASDAQ: MRSNsigned a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany's Merck KGaA (OTC: MKGAF) (OTC: MKKGY).

  • Mersana would receive $30 million in an upfront payment and up to $800 million in development, regulatory and commercial milestones.

  • RelatedMersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy.

  • Under the agreement, Mersana would develop cancer drug candidates against up to two targets that would utilize its platform to combine Merck KGaA's proprietary antibodies.

  • Pre-clinical activities will be split between the companies. Merck Germany will be solely responsible for all clinical development and potential commercialization activities relating to any resulting product candidates.

  • Mersana said it was also eligible to receive royalties of up to low double-digit percentages on global net sales for any approved ADCs developed under the agreement.

  • Price Action: MRSN shares are down 2.68% at $5.82 on the last check Friday.

  • Photo Via Company

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.